Clinical snapshot — for veterinary teams
- Active ingredient / class: frunevetmab — felinized anti–nerve growth factor (anti-NGF) monoclonal antibody (biologic); the first mAb FDA-approved for cats
- Indication: control of pain associated with osteoarthritis in cats
- Administration: subcutaneous injection given in-clinic, dosed by weight (1.0 mg/kg), once monthly
- Onset / kinetics: improvement often within 1–2 weeks; steady-state after ~2 doses
- Clearance: degraded via normal protein catabolism — not liver/kidney metabolized, which makes it attractive for senior cats and those with CKD where long-term NSAIDs are risky
- Monitoring windows that matter: mobility/response over the first 1–2 cycles; monthly re-injection scheduling; watch for injection-site and skin reactions
- Counsel clients on: generally well tolerated; most common effects are vomiting, injection-site pain, and skin signs (dermatitis, scabbing, pruritus); anti-drug antibodies can reduce efficacy over time; safe concurrent NSAID use not established
Plain answer for owners who landed here: Solensia is usually very well tolerated. The most commonly reported effects are mild — vomiting, tenderness at the injection site, or minor skin irritation. It’s a monthly injection given at your vet, and many cats move more comfortably within one to two weeks. Because it isn’t processed by the liver or kidneys, it’s often used in older cats that can’t take other pain medications.
What it’s used for — and why clients call about it
Solensia is a monthly injection that neutralizes NGF, a key driver of osteoarthritis pain — and it filled a real gap, because cats tolerate long-term NSAIDs poorly and OA pain in cats is badly underdiagnosed. Cats hide pain, so the owner’s read on whether it’s working is often subtle (jumping again, using the litter box more easily, less hiding). That makes follow-up unusually valuable here: the clinic needs the owner’s at-home observations to know whether the injection is doing its job and when the next one is due.
The adverse-event and monitoring profile
Per the FDA-approved labeling (Zoetis), Solensia is generally well tolerated; the most frequently reported reactions were vomiting and injection-site pain, with some skin signs (dermatitis, scabbing of the head and neck, pruritus). Because it’s a monoclonal antibody cleared by normal protein breakdown rather than the liver or kidneys, it’s a practical option for senior and CKD cats. Two caveats belong in counseling: anti-frunevetmab antibodies can develop and reduce effectiveness over time, and the safe use of Solensia alongside NSAIDs has not been established in cats. As an anti-NGF therapy, it sits in the same broad class as canine Librela; rapidly progressing osteoarthritis has been reported in human anti-NGF trials but has not been characterized in cats, and long-term effects beyond six months are not fully evaluated. (Sources: Solensia FDA-approved labeling via Drugs.com; VCA Animal Hospitals; PetMD.)
The follow-up window that matters
Two windows. The first one to two cycles establish whether mobility actually improves — and because cats mask pain, this depends almost entirely on structured owner observation at home. Then monthly re-injection timing is the recurring task: the effect is designed to be sustained with on-schedule dosing, and a lapse lets pain creep back before the owner necessarily connects it to a missed appointment.
What to ask clients at follow-up
A focused monthly check covers:
- Is your cat moving more easily — jumping, using stairs, getting in and out of the litter box, grooming?
- Any vomiting, or redness, swelling, or scabbing where the injection was given?
- Any new skin irritation or over-grooming?
- Is the next monthly injection booked?
Those mobility questions are the structured outcome data the clinic can’t get any other way, and the re-injection prompt is the single highest-leverage thing to automate for an in-clinic monthly biologic.
Where compliance breaks down
Because Solensia is administered at the clinic, the failure mode is a missed monthly appointment, not a forgotten pill. Owners also under-report improvement simply because feline pain is hard to read, so a cat who’s genuinely benefiting can look “unchanged” and the owner quietly disengages. Capturing real at-home mobility signals and prompting the next visit on time keeps both the patient comfortable and the protocol on track.
Standardizing this follow-up without adding staff time
This is a clean fit for Nidana Loop. After each Solensia injection, Loop calls or texts the owner to capture concrete mobility observations and screen for vomiting or injection-site and skin reactions, returns those as a structured note to the clinic, and flags concerns for a vet. As the month closes, it prompts the owner to re-book before pain returns — turning a hard-to-read feline pain picture and an easy-to-miss appointment into documented, scheduled touchpoints, with no staff calls.
See Loop handle medication follow-up
Loop runs your post-injection check-ins, captures at-home mobility response, and prompts monthly re-booking automatically — returning structured outcomes to the clinic. Book a 20-minute demo → · See how Loop works →
For pet owners
How often does my cat need Solensia? Once a month, as an injection at your veterinary clinic.
How quickly will it work? Many cats show improved movement within 1–2 weeks, with best results after a couple of doses.
Is it safe for an older cat with kidney issues? It isn’t processed by the liver or kidneys, which is part of why it’s often chosen for senior cats — but your vet will assess your individual cat.
What if I miss the monthly appointment? Contact your vet to reschedule; your cat may show more arthritis discomfort until the next injection.
This article is general information, not veterinary advice. Owners should consult their veterinarian and follow the product’s FDA-approved label.
Sources: Solensia (frunevetmab) FDA-approved labeling via Drugs.com; VCA Animal Hospitals — frunevetmab; PetMD.